{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T21:35:39Z","timestamp":1789767339622,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Arthritis Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R41DK131681"],"award-info":[{"award-number":["R41DK131681"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT2001027"],"award-info":[{"award-number":["GNT2001027"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["GNT1135837"],"award-info":[{"award-number":["GNT1135837"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011769","name":"Scripps Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004752","name":"State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004752","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bcp.2024.116401","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T13:44:50Z","timestamp":1719582290000},"page":"116401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology"],"prefix":"10.1016","volume":"227","author":[{"given":"Irina U.","family":"Agoulnik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Kaftanovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross A.D.","family":"Bathgate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Kocan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"DiStefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Agoulnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2024.116401_b0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.114.009472","article-title":"International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1\u20134, the receptors for relaxin family peptides","volume":"67","author":"Halls","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bcp.2024.116401_b0010","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2018.02.008","article-title":"The relaxin receptor as a therapeutic target - perspectives from evolution and drug targeting","volume":"187","author":"Bathgate","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.bcp.2024.116401_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114884","article-title":"Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions","volume":"197","author":"Samuel","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.bcp.2024.116401_b0020","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bph.12964","article-title":"Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins","volume":"172","author":"Sarwar","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116401_b0025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/mol.105.021691","article-title":"Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms","volume":"70","author":"Halls","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"8","key":"10.1016\/j.bcp.2024.116401_b0030","doi-asserted-by":"crossref","first-page":"e42714","DOI":"10.1371\/journal.pone.0042714","article-title":"Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS","volume":"7","author":"Chow","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.bcp.2024.116401_b0035","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1111\/bph.12623","article-title":"Signalling profiles of H3 relaxin, H2 relaxin and R3(BDelta23-27)R\/I5 acting at the relaxin family peptide receptor 3 (RXFP3)","volume":"171","author":"Kocan","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116401_b0040","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41598-017-02916-5","article-title":"ML290 is a biased allosteric agonist at the relaxin receptor RXFP1","volume":"7","author":"Kocan","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.bcp.2024.116401_b0045","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bph.13529","article-title":"Anti-fibrotic actions of relaxin","volume":"174","author":"Samuel","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2024.116401_b0050","series-title":"Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: Induction of MMP-9 involves the PI3K","author":"Ahmad","year":"2012"},{"issue":"3","key":"10.1016\/j.bcp.2024.116401_b0055","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1566524021666210309113650","article-title":"Human Recombinant Relaxin (Serelaxin) as Anti-fibrotic Agent: Pharmacology","volume":"22","author":"Sassoli","year":"2022","journal-title":"Limitations and Actual Perspectives, Curr Mol Med"},{"issue":"1","key":"10.1016\/j.bcp.2024.116401_b0060","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.2013.518","article-title":"Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis","volume":"86","author":"Chow","year":"2014","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.bcp.2024.116401_b0065","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/labinvest.2010.198","article-title":"Relaxin remodels fibrotic healing following myocardial infarction","volume":"91","author":"Samuel","year":"2011","journal-title":"Lab Invest"},{"issue":"10","key":"10.1016\/j.bcp.2024.116401_b0070","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1210\/en.2010-0286","article-title":"Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis","volume":"151","author":"Hewitson","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2024.116401_b0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1749-6632.2008.03780.x","article-title":"Reversal of cardiac fibrosis and related dysfunction by relaxin","volume":"1160","author":"Du","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.bcp.2024.116401_b0080","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1749-6632.2008.03783.x","article-title":"Relaxin reduces fibrosis in models of progressive and established hepatic fibrosis","volume":"1160","author":"Bennett","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"10.1016\/j.bcp.2024.116401_b0085","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1210\/en.2008-0250","article-title":"Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy","volume":"149","author":"Samuel","year":"2008","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.bcp.2024.116401_b0090","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00018-007-6543-y","article-title":"Drugs of the future: the hormone relaxin","volume":"64","author":"Samuel","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bcp.2024.116401_b0095","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/978-0-387-74672-2_7","article-title":"The effects of relaxin on extracellular matrix remodeling in health and fibrotic disease","volume":"612","author":"Samuel","year":"2007","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116401_b0100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.HYP.0000171930.00697.2f","article-title":"Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats","volume":"46","author":"Lekgabe","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2024.116401_b0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-020-00836-6","article-title":"Hepatic macrophages act as a central hub for relaxin-mediated alleviation of liver fibrosis","author":"Hu","year":"2021","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/j.bcp.2024.116401_b0110","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep.26627","article-title":"Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo","volume":"59","author":"Fallowfield","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.bcp.2024.116401_b0115","first-page":"416","article-title":"Relaxin decreases the severity of established hepatic fibrosis in mice, Liver international : official journal of the International Association for the Study of the","volume":"34","author":"Bennett","year":"2014","journal-title":"Liver"},{"issue":"4","key":"10.1016\/j.bcp.2024.116401_b0120","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jcph.433","volume":"55","author":"Dahlke","year":"2015","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1016\/j.bcp.2024.116401_b0125","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cardfail.2009.01.008","article-title":"Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial","volume":"15","author":"Dschietzig","year":"2009","journal-title":"J Card Fail"},{"issue":"7","key":"10.1016\/j.bcp.2024.116401_b0130","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1016\/j.bcp.2024.116401_b0135","doi-asserted-by":"crossref","unstructured":"J.R. Teerlink, G. Cotter, B.A. Davison, G.M. Felker, G. Filippatos, B.H. Greenberg, P. Ponikowski, E. Unemori, A.A. Voors, K.F. Adams, Jr., M.I. Dorobantu, L.R. Grinfeld, G. Jondeau, A. Marmor, J. Masip, P.S. Pang, K. Werdan, S.L. Teichman, A. Trapani, C.A. Bush, R. Saini, C. Schumacher, T.M. Severin, M. Metra, R.E.i.A.H.F. Investigators, Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial, Lancet 381(9860) (2013) 29-39.","DOI":"10.1016\/S0140-6736(12)61855-8"},{"issue":"8","key":"10.1016\/j.bcp.2024.116401_b0140","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of Serelaxin in Patients with Acute Heart Failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.bcp.2024.116401_b0145","doi-asserted-by":"crossref","first-page":"e013465","DOI":"10.1161\/JAHA.119.013465","article-title":"Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart","volume":"8","author":"Sun","year":"2019","journal-title":"Journal of the American Heart Association"},{"key":"10.1016\/j.bcp.2024.116401_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.nano.2018.12.008","article-title":"Engineered Relaxin as theranostic nanomedicine to diagnose and ameliorate liver cirrhosis","volume":"17","author":"Nagorniewicz","year":"2019","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.bcp.2024.116401_b0155","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1021\/acs.bioconjchem.8b00764","article-title":"Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs","volume":"30","author":"Muppidi","year":"2019","journal-title":"Bioconjug Chem"},{"issue":"4","key":"10.1016\/j.bcp.2024.116401_b0160","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/acs.jmedchem.0c01533","article-title":"Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases","volume":"64","author":"Mallart","year":"2021","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bcp.2024.116401_b0165","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/bph.16055","article-title":"Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure","volume":"180","author":"Verdino","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116401_b0170","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1038\/s41598-022-24716-2","article-title":"Characterization of a new potent and long-lasting single chain peptide agonist of RXFP1 in cells and in vivo translational models","volume":"12","author":"Illiano","year":"2022","journal-title":"Scientific Reports"},{"key":"10.1016\/j.bcp.2024.116401_b0175","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/ncomms2953","article-title":"Identification and optimization of small-molecule agonists of the human relaxin hormone receptor RXFP1","volume":"4","author":"Xiao","year":"2013","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.bcp.2024.116401_b0180","doi-asserted-by":"crossref","first-page":"12435","DOI":"10.1096\/fj.201901046R","article-title":"Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis","volume":"33","author":"Kaftanovskaya","year":"2019","journal-title":"FASEB J"},{"issue":"8","key":"10.1016\/j.bcp.2024.116401_b0185","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.chembiol.2015.07.011","article-title":"A General Method for Insertion of Functional Proteins within Proteins via Combinatorial Selection of Permissive Junctions","volume":"22","author":"Peng","year":"2015","journal-title":"Chem Biol"},{"issue":"2","key":"10.1016\/j.bcp.2024.116401_b0190","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bbrc.2012.02.141","article-title":"Site-specific conjugation of a lanthanide chelator and its effects on the chemical synthesis and receptor binding affinity of human relaxin-2 hormone","volume":"420","author":"Shabanpoor","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.bcp.2024.116401_b0195","first-page":"1148","article-title":"Human relaxin gene 3 (H3) and the equivalent mouse relaxin (M3) gene","volume":"277","author":"Bathgate","year":"2002","journal-title":"Novel Members of the Relaxin Peptide Family, J Biol Chem"},{"issue":"6","key":"10.1016\/j.bcp.2024.116401_b0200","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1210\/js.2017-00112","article-title":"Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290","volume":"1","author":"Kaftanovskaya","year":"2017","journal-title":"J Endocr Soc"},{"issue":"1 Suppl","key":"10.1016\/j.bcp.2024.116401_b0205","first-page":"25","article-title":"ImageJ for microscopy","volume":"43","author":"Collins","year":"2007","journal-title":"Biotechniques"},{"key":"10.1016\/j.bcp.2024.116401_b0210","article-title":"Targeting the relaxin\/insulin-like family peptide receptor 1 and 2 with small molecule compounds","author":"Ng","year":"2018","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bcp.2024.116401_b0215","doi-asserted-by":"crossref","DOI":"10.1111\/bph.16338","article-title":"R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases","author":"Poirier","year":"2024","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.bcp.2024.116401_b0220","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1038\/s41598-018-23481-5","article-title":"In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor","volume":"8","author":"Seijsing","year":"2018","journal-title":"Scientific Reports"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224003848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:59:42Z","timestamp":1777377582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224003848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":44,"alternative-id":["S0006295224003848"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116401","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116401"}}